"Pancreatic Neoplasms" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).
Descriptor ID |
D010190
|
MeSH Number(s) |
C04.588.274.761 C04.588.322.475 C06.301.761 C06.689.667 C19.344.421
|
Concept/Terms |
Pancreatic Neoplasms- Pancreatic Neoplasms
- Neoplasm, Pancreatic
- Pancreatic Neoplasm
- Pancreas Neoplasms
- Neoplasm, Pancreas
- Neoplasms, Pancreas
- Pancreas Neoplasm
- Neoplasms, Pancreatic
Cancer of Pancreas- Cancer of Pancreas
- Pancreas Cancers
- Pancreas Cancer
- Cancer, Pancreas
- Cancers, Pancreas
- Pancreatic Cancer
- Cancer, Pancreatic
- Cancers, Pancreatic
- Pancreatic Cancers
- Cancer of the Pancreas
|
Below are MeSH descriptors whose meaning is more general than "Pancreatic Neoplasms".
Below are MeSH descriptors whose meaning is more specific than "Pancreatic Neoplasms".
This graph shows the total number of publications written about "Pancreatic Neoplasms" by people in this website by year, and whether "Pancreatic Neoplasms" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 7 | 1 | 8 |
1995 | 13 | 3 | 16 |
1996 | 12 | 5 | 17 |
1997 | 14 | 2 | 16 |
1998 | 24 | 5 | 29 |
1999 | 16 | 3 | 19 |
2000 | 14 | 4 | 18 |
2001 | 35 | 1 | 36 |
2002 | 40 | 5 | 45 |
2003 | 62 | 6 | 68 |
2004 | 52 | 4 | 56 |
2005 | 85 | 6 | 91 |
2006 | 71 | 5 | 76 |
2007 | 89 | 10 | 99 |
2008 | 89 | 11 | 100 |
2009 | 96 | 11 | 107 |
2010 | 99 | 12 | 111 |
2011 | 111 | 14 | 125 |
2012 | 119 | 7 | 126 |
2013 | 101 | 10 | 111 |
2014 | 112 | 6 | 118 |
2015 | 107 | 6 | 113 |
2016 | 107 | 9 | 116 |
2017 | 107 | 5 | 112 |
2018 | 99 | 13 | 112 |
2019 | 108 | 7 | 115 |
2020 | 109 | 5 | 114 |
2021 | 102 | 3 | 105 |
2022 | 107 | 0 | 107 |
2023 | 92 | 3 | 95 |
2024 | 75 | 2 | 77 |
To return to the timeline,
click here.
Below are the most recent publications written about "Pancreatic Neoplasms" by people in Profiles.
-
Surgery for Borderline Resectable Pancreatic Ductal Adenocarcinoma: Preoperative Planning, Technical Considerations, and Building a Program. Surg Clin North Am. 2024 Oct; 104(5):1031-1048.
-
Pancreatic Epithelial IL17/IL17RA Signaling Drives B7-H4 Expression to Promote Tumorigenesis. Cancer Immunol Res. 2024 Sep 03; 12(9):1170-1183.
-
The KRAS mutational spectrum and its clinical implications in pancreatic cancer. Cancer Cell. 2024 Sep 09; 42(9):1494-1496.
-
MIF/NR3C2 axis regulates glucose metabolism reprogramming in pancreatic cancer through MAPK-ERK and AP-1 pathways. Carcinogenesis. 2024 Aug 12; 45(8):582-594.
-
The Sequencing Conundrum in Localized Pancreatic Adenocarcinoma-Progress or Passive Acceptance? JAMA Oncol. 2024 Aug 01; 10(8):1036-1037.
-
The liver casts a wide NET for metastatic pancreatic cancer. Nat Med. 2024 Aug; 30(8):2125-2126.
-
Pancreatic stellate cells and the interleukin family: Linking fibrosis and immunity to pancreatic ductal adenocarcinoma (Review). Mol Med Rep. 2024 09; 30(3).
-
TSG-6+ cancer-associated fibroblasts modulate myeloid cell responses and impair anti-tumor response to immune checkpoint therapy in pancreatic cancer. Nat Commun. 2024 Jul 10; 15(1):5291.
-
Effect of surgical approach on early return to intended oncologic therapy after resection for pancreatic ductal adenocarcinoma. Surg Endosc. 2024 Sep; 38(9):4986-4995.
-
Circulating KRAS G12D but not G12V is associated with survival in metastatic pancreatic ductal adenocarcinoma. Nat Commun. 2024 Jul 09; 15(1):5763.